PPAR Subtypes and Their Therapeutic Agents
The three PPAR isoforms (α, γ, and δ) are nuclear transcription factors that regulate glucose and lipid metabolism, with distinct therapeutic applications: PPAR-α agonists (fibrates) for dyslipidemia, PPAR-γ agonists (thiazolidinediones) for insulin resistance, and emerging pan-PPAR agonists showing promise for metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes. 1
PPAR-α: Lipid Metabolism and Cardiovascular Effects
PPAR-α is predominantly expressed in oxidative tissues and regulates:
- Triglyceride reduction and HDL cholesterol elevation through enhanced fatty acid β-oxidation 2
- Cholesterol transport to mitochondria for neurosteroid biosynthesis 3
- Gene transcription related to fatty acid metabolism and mitochondrial biogenesis 4
Therapeutic Agents: Fibrates
Fibrates (fenofibrate, pemafibrate) activate PPAR-α and have been used since the 1970s for lipid modification 2. However, the PROMINENT trial with pemafibrate failed to demonstrate cardiovascular benefit in preventing major adverse cardiovascular events, raising questions about PPAR-α's role in cardiovascular risk reduction 4. Evidence suggests potential benefit specifically for peripheral artery disease 4.
PPAR-γ: Insulin Sensitivity and Glucose Homeostasis
PPAR-γ has highest expression in white adipose tissue and regulates:
- Insulin sensitivity improvement through modulation of free fatty acid flux 2
- Lipogenesis and adipocyte differentiation 5
- Adiponectin levels and glucose metabolism 6
Therapeutic Agents: Thiazolidinediones (TZDs)
TZDs (pioglitazone, rosiglitazone) are PPAR-γ agonists used for type 2 diabetes treatment 1. The major limitation is their adverse effect profile including edema, bone fractures, and potential heart failure exacerbation 1.
Next-Generation Approaches
To mitigate TZD side effects, selective PPAR-γ modulators (SPPARγMs) and partial agonists are being developed to induce beneficial metabolic effects while avoiding adverse outcomes 4, 7. These agents aim to activate PPAR-γ in a tissue-specific manner, affecting only selected metabolic pathways 7.
PPAR-δ (β/δ): Energy Balance and Oxidative Metabolism
PPAR-δ is expressed in oxidative tissues and promotes:
- Fatty acid β-oxidation in liver 6
- Substrate delivery and oxidative phosphorylation 5
- Energy homeostasis regulation 8
PPAR-δ remains under investigation as a therapeutic target, with its full clinical potential not yet established 2.
Pan-PPAR Agonists: Multi-Target Approach
Pan-PPAR agonists simultaneously activate all three PPAR subtypes, aiming to combine therapeutic benefits while balancing tolerability 1, 7.
Chiglitazar: Leading Pan-PPAR Agent
In a phase 3 randomized trial, chiglitazar (32 mg and 48 mg) demonstrated non-inferiority to sitagliptin 100 mg for HbA1c reduction in type 2 diabetes, with HbA1c decreases of 0.04% and 0.08% greater than sitagliptin, respectively 1. The adverse event profile was favorable, with most events being mild and low discontinuation rates 1.
MASH Treatment
For metabolic dysfunction-associated steatohepatitis, pan-PPAR agonism appears necessary to achieve significant histological improvements 1, 4. This multi-target approach addresses:
- Hepatic fat reduction
- Decreased inflammation and liver enzymes
- Improved liver histology 1
Clinical Algorithm for PPAR-Based Therapy
For dyslipidemia with elevated triglycerides: Consider PPAR-α agonists (fibrates), but recognize limited cardiovascular event reduction based on PROMINENT trial results 4.
For type 2 diabetes with insulin resistance:
- First-line PPAR-γ activation via TZDs only if edema, fracture risk, and heart failure are not concerns 1
- Consider pan-PPAR agonists like chiglitazar as alternative with improved safety profile 1
For MASH: Pan-PPAR agonists are preferred over single-target agents to achieve meaningful histological endpoints 1, 4.
Critical Caveats
Avoid TZDs in patients with:
- Existing heart failure (any class) due to fluid retention risk 1
- Osteoporosis or high fracture risk 1
- Significant edema 1
The failure of selective PPAR-α agonism (pemafibrate) in cardiovascular outcomes trials indicates that lipid modification alone may be insufficient for cardiovascular protection 4. This contrasts with the proven cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in diabetes management 1.